Novel anti-viral activity of SB 9200, a RIGI agonist; results from Cohort 1 of the ACHIEVE trial

Conference Reports for NATAP

The Liver Meeting
Washington DC
October 2017


Novel anti-viral activity of SB 9200, a RIGI agonist; results from Cohort 1 of the ACHIEVE trial

	Reported by Jules Levin AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC Poster pdf attached Prof. Stephen Locarnini Download the PDF